Biovaxys Technology Corp Stock Performance
| BVAXF Stock | USD 0.04 0 8.72% |
The firm shows a Beta (market volatility) of 2.15, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biovaxys Technology will likely underperform. Biovaxys Technology Corp right now shows a risk of 6.65%. Please confirm Biovaxys Technology Corp maximum drawdown, as well as the relationship between the accumulation distribution and day typical price , to decide if Biovaxys Technology Corp will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Biovaxys Technology Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Biovaxys Technology is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 2.4 M |
Biovaxys |
Biovaxys Technology Relative Risk vs. Return Landscape
If you would invest 4.48 in Biovaxys Technology Corp on September 12, 2024 and sell it today you would lose (0.50) from holding Biovaxys Technology Corp or give up 11.16% of portfolio value over 90 days. Biovaxys Technology Corp is currently producing 0.0259% returns and takes up 6.652% volatility of returns over 90 trading days. Put another way, 59% of traded otc stocks are less volatile than Biovaxys, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Biovaxys Technology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biovaxys Technology's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Biovaxys Technology Corp, and traders can use it to determine the average amount a Biovaxys Technology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0039
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BVAXF |
Estimated Market Risk
| 6.65 actual daily | 59 59% of assets are less volatile |
Expected Return
| 0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biovaxys Technology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biovaxys Technology by adding Biovaxys Technology to a well-diversified portfolio.
Biovaxys Technology Fundamentals Growth
Biovaxys OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Biovaxys Technology, and Biovaxys Technology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biovaxys OTC Stock performance.
| Return On Equity | -0.73 | |||
| Return On Asset | -0.38 | |||
| Current Valuation | 11.35 M | |||
| Shares Outstanding | 106.72 M | |||
| Price To Earning | (4.32) X | |||
| Price To Book | 2.53 X | |||
| EBITDA | (6.44 M) | |||
| Cash And Equivalents | 39.05 K | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (5.29 M) | |||
| Earnings Per Share | (0.05) X | |||
| Total Asset | 8.5 M | |||
| Retained Earnings | (80 M) | |||
| Current Asset | 37 M | |||
| Current Liabilities | 2 M | |||
About Biovaxys Technology Performance
By analyzing Biovaxys Technology's fundamental ratios, stakeholders can gain valuable insights into Biovaxys Technology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biovaxys Technology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biovaxys Technology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320 and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. BIOVAXYS TECHNOLOGY is traded on OTC Exchange in the United States.Things to note about Biovaxys Technology Corp performance evaluation
Checking the ongoing alerts about Biovaxys Technology for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Biovaxys Technology Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biovaxys Technology had very high historical volatility over the last 90 days | |
| Biovaxys Technology has some characteristics of a very speculative penny stock | |
| Biovaxys Technology has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.16, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Biovaxys Technology until it has trouble settling it off, either with new capital or with free cash flow. So, Biovaxys Technology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biovaxys Technology Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biovaxys to invest in growth at high rates of return. When we think about Biovaxys Technology's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (6.46 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biovaxys Technology Corp has accumulated about 39.05 K in cash with (5.29 M) of positive cash flow from operations. | |
| Roughly 19.0% of the company shares are held by company insiders |
- Analyzing Biovaxys Technology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biovaxys Technology's stock is overvalued or undervalued compared to its peers.
- Examining Biovaxys Technology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biovaxys Technology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biovaxys Technology's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Biovaxys Technology's otc stock. These opinions can provide insight into Biovaxys Technology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biovaxys OTC Stock analysis
When running Biovaxys Technology's price analysis, check to measure Biovaxys Technology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biovaxys Technology is operating at the current time. Most of Biovaxys Technology's value examination focuses on studying past and present price action to predict the probability of Biovaxys Technology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biovaxys Technology's price. Additionally, you may evaluate how the addition of Biovaxys Technology to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |